Compared to current targeted therapies, which often address single genetic mutations (e.g., FLT3, IDH1/2), the multi-targeted nature of YWLS-derived compounds offers broader anti-leukemia effects and may overcome the limitation of clonal heterogeneity. The gene discussed is IDH1; the disease is leukemia.